Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the target of a large drop in short interest in October. As of October 15th, there was short interest totalling 17,400 shares, a drop of 19.4% from the September 30th total of 21,600 shares. Approximately 2.8% of the company’s stock are sold short. Based on an average daily volume of 11,100 shares, the short-interest ratio is presently 1.6 days.
Arcadia Biosciences Trading Up 9.1 %
Shares of RKDA stock traded up $0.39 on Friday, reaching $4.70. 88,983 shares of the company’s stock were exchanged, compared to its average volume of 18,855. The company’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $2.81. The stock has a market capitalization of $6.41 million, a PE ratio of -0.91 and a beta of 1.34. Arcadia Biosciences has a 52 week low of $1.85 and a 52 week high of $5.34.
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The firm had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same quarter in the prior year, the business posted ($2.64) EPS. As a group, sell-side analysts predict that Arcadia Biosciences will post -1.7 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Report on RKDA
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
See Also
- Five stocks we like better than Arcadia Biosciences
- What to Know About Investing in Penny Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Find Undervalued Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The Basics of Support and Resistance
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.